Efficacy and safety of treatment with Dolutegravir in the therapy of Virus Human Immunodeficiency
DOI:
https://doi.org/10.31243/mdc.uta.v9i3.2755.2025Keywords:
VIRUS DE INMUNODEFICIENCIA HUMANA, TRATAMIENTO, DOLUTEGRAVIRAbstract
The human immunodeficiency virus (HIV) is responsible for the largest epidemic of this century, the first cases were diagnosed in the United States during the 1980s; Its advanced phase is Acquired Immune Deficiency Syndrome (AIDS) and is characterized by a CD4 lymphocyte count, resulting in a depressed immune system. The objective of this study is to analyze the efficacy and safety of treatment with Dolutegravir in the management of HIV, considering its adverse effects and specific clinical aspects. This is a bibliographic review of the literature updated from January 2018 to 2024 in the PubMed, Scopus, Web of Science and ScieLO databases. Dolutegravir is an inhibitor of viral integrase, a critical enzyme that catalyzes the integration of viral DNA into the genome of host cells. Blocking this enzyme prevents the virus from inserting into the DNA of human cells, which stops viral replication. This effect reduces the viral load in the body and allows the recovery and preservation of the patient's immune system. Dolutegravir has strong clinical efficacy in addition to low rates of drug resistance and minor side effects. In Conclusion Dolutegravir has shown superiority in viral suppression compared to other established treatments, making it a preferred option in the initial treatment of HIV.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jairo Andres Salvatierra Andino, Alexandra Laguapillo Vergara
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
